Navigation Links
PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Date:12/6/2012

rough the Muscular Dystrophy Association (www.mdausa.org), Parent Project Muscular Dystrophy (www.parentprojectmd.org), Action Duchenne (www.actionduchenne.org), United Parent Projects Muscular Dystrophy (uppmd.org), Muscular Dystrophy Campaign (www.muscular-dystrophy.org) and AFM (l'Association francaise contre les myopathies), (www.afm-telethon.fr).

About Ataluren
Ataluren, an investigational new drug discovered and developed by PTC Therapeutics, is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in nmDMD. The development of ataluren has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA's Office of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PT
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013  The Lupus ... conference devoted to advancing new treatments for lupus nephritis, ... 60 percent of patients. The conference launched a new ... the Lupus Nephritis Trials Network (LNTN). More ... and the kidney came together to focus on two ...
(Date:5/22/2013)... , May 22, 2013 The new ... safe as the previous version used prior to 2010, ... Kaiser Permanente study published today in Vaccine. ... use beginning in 2010 after a series of trials. ... broader range of pneumococcal types than the previously used ...
(Date:5/22/2013)... , May 22, 2013  Healthcare ... enterprise content management (ECM) solution, ... Hospital Information System .  These organizations identified ... system and will use OnBase to optimize ... initiatives.   (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO ...
Breaking Medicine Technology:Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3
... Colorado Cancer,Research Program (CCRP) invites golfers to participate in its ... at the Valley Country Club,14601 Country Club Drive, Aurora. The ... been the home to major events such as the,Colorado Women,s ... professional,golfers have been inducted into the Colorado Hall of Fame., ...
... TAMPA, Fla., April 27 Calvin A. ... from his 60-patient,retrospective case control study that ... Xibrom(TM) (bromfenac 0.09mg ophthalmic solution) in Lucentis(R),(ranibizumab) ... degeneration (AMD) in an oral poster presentation ...
Cached Medicine Technology:Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 2Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... more likely to attempt suicide, whether or not they ... to a new study. "Clinicians who are seeing ... are at increased risk of suicide," said study co-author ... Treatment Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... Rapids, IA (PRWEB) May 22, 2013 ... theatre piece Handicap This! The performance promotes awareness ... their dreams. The Handicap This! performance will be held ... Mar High School auditorium. Tickets for Handicap This! ... Handicap This! helps audiences measure the level to which ...
(Date:5/22/2013)... SAN FRANCISCO Researchers in genomic health disparities from ... the Stanford University School of Medicine have teamed up ... Conference to Eliminate Health Disparities in Genomic Medicine." ... role of nonprofits, business and government to reduce these ... of the United States, individuals within underserved groups continue ...
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... has established the Westchester Lung Nodule Center for ... or receive lung cancer care. Lung cancer is the deadliest ... year, more people in the U.S. die from lung cancer ... As with all cancers, early detection increases survival rates. ...
Breaking Medicine News(10 mins):Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3
... eCare, an initiative that employs information,and advanced technologies ... care, WILLIAMSBURG, Va., June 18 The ... and Mary proudly announces that,Professor Dorothea La "Chon" ... awards available to a faculty member in a ...
... source; New York City links 7 infections to salmonella ... number of people known to have fallen ill after ... 30 states plus the District of Columbia, U.S. health ... not due to new infections but mainly because some ...
... Corporation,(Nasdaq: AIRM ), the largest air medical ... Executive Officer Aaron Todd and Chief,Financial Officer Trent ... Conference in New York City on Tuesday, June ... can listen to the presentation via a live ...
... strike small percentage of patients , , WEDNESDAY, June 18 ... new side effect associated with the cancer drug Gleevec ... leukemia and gastrointestinal stromal tumors. , In a letter ... New England Journal of Medicine , the doctors describe ...
... seizures, SPOKANE, Wash., June 18 The Epilepsy,Foundation ... this Saturday, June 21 in Spokane at Riverfront Park ... from 9:30 am - 12:30 pm., "Everyone is ... with epilepsy," said Ryan Oelrich, Program Manager. "We are ...
... Berkeley The newly sequenced genome of a dainty, quill-like ... that vertebrates evolved over the past 550 million years through ... ,The late geneticist Susumu Ohno argued in 1970 ... evolution of higher organisms, and Ohno,s theory was the basis ...
Cached Medicine News:Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 2Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 3Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 4Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 5Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 2Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 3Health News:Cancer Drug Gleevec Linked to Muscle Damage 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 3Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: